Fisher Wallace

About the offering

Arriving in 2025, OAK was born from 15 years of R&D, millions of hours of real-world Version 1.0 usage, and a relentless focus on making wearable brain stimulation not only scalable, but desirable. Proven as the most rapid self-administered treatment for depression and anxiety, and capable of improving a universe of conditions, OAK is designed to provide lifelong brain health. Clinically Proven: The results of our 255-subject, triple-blind, randomized, controlled trial, published in The Journal of Clinical Psychiatry, prove our Version 2.0 wearable significantly reduces depression in the first week of treatment. A separate 220-subject, 8-week trial for the treatment of anxiety, conducted by the Seattle Police Department and Washington State University, achieved its primary endpoint and will be used to obtain regulatory clearance in the US and Europe in 2025 (journal publication is pending). Proof-of-Concept: Under temporary FDA clearance, we distributed 100,000 proof-of-concept devices via 14,000 prescribers, and obtained Medicaid reimbursement in Maine (MaineCare). We are now engaged in obtaining regulatory approval for OAK, our Version 2.0 wearable that was designed in collaboration with the teams behind Beats, Nest and the HoloLens. Sign up to receive updates about OAK. We are a patient-owned healthcare company - Join Us Sign up to receive a monthly update on OAK and the future of mental healthcare.

FAQ